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Abstract: There is an increasing prevalence of diabetes worldwide and substance abuse has been
observed as a problem among some people with diabetes. Therefore, there is an urgent need to
understand the association between unhealthy drug use including the abuse of opium and clinical
outcomes including its impact on lipid profile in patients with diabetes as the presence of these
conditions can increase the risk of cardiovascular morbidity and mortality. Aim: This was a systematic
review and meta-analysis which evaluated the impact of opium abuse on lipid profile in patients with
diabetes. Method: This systematic review was conducted in line with the preferred reporting items
for systematic reviews and meta-analyses (PRISMA) guidelines. Three databases (Embase, PubMed,
and PsycINFO) plus Google Scholar were searched for relevant articles from database inception to
18 July 2019 based on the Population, Intervention, Comparator, and Outcomes (PICO) framework.
The studies included were based on a set of inclusion and exclusion criteria including patients with
diabetes who abused opium. Articles were evaluated for risk of bias and the meta-analysis was
conducted using Revman. Results: Six articles that met the criteria were included in the systematic
review and meta-analysis. The type of substance abused was opium in all the studies. The results
of the meta-analysis showed that opium abuse significantly (P = 0.01) lowered total cholesterol
compared to control with a mean difference of −0.17 (95% CI, −0.29, −0.04) in patients with diabetes.
With respect to high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol,
triglycerides, and body mass index, the differences were not statistically significant (P > 0.05) between
those who abused opium compared with the control. Nutritional deficiencies, weight loss and
lipid dysregulation due to liver dysfunction which are found in people who abuse substances may
explain the findings of the current review with respect to lipid profile in patients with diabetes who
abuse opium compared with the control. Conclusion: The findings of this systematic review and
meta-analysis have shown that opium abuse significantly decreased total cholesterol (P < 0.05) in
patients with diabetes. However, the effect of opium abuse on HDL cholesterol, triglycerides, body
mass index (BMI) and LDL cholesterol in these patients were not statistically significant (P > 0.05)
compared with the control. This result has public health significance in terms of ensuring the
promotion of adequate nutritional intake in patients with diabetes who abuse opium.
Keywords: diabetes; substance abuse; opioids; total cholesterol; HDL cholesterol; LDL cholesterol;
triglyceride; meta-analysis; systematic review; body mass index
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1. Introduction
There is an increasing prevalence of diabetes worldwide and this presents a significant public
health challenge [1,2]. In 2014, there were 422 million people who were living with diabetes compared
to 108 million people in 1980, representing a global increase in the prevalence of diabetes from 4.7%
in 1980 to 8.5% in 2014 among the adult population [1]. In addition, diabetes is projected to be the
seventh leading cause of death by 2030 [3]. There is evidence of increased risks and poorer diabetes
quality of care which have been associated with substance abuse among patients with diabetes [3–5].
1.1. Why is the Review Important?
Shiri et al. [6] showed that opium abuse was a common problem among some people with
diabetes, while Kim et al. [7] noted that substance abuse was on the increase globally and individuals
who abuse substances are at increased risk of worse hypertension and diabetes outcomes. Therefore,
it is essential to understand the association between unhealthy drug use and the clinical outcomes
due to its public health significance including its impact on markers of cardiovascular diseases
such as total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol,
and triglycerides [7]. Patients with diabetes and poor lipid profile are at increased risk of cardiovascular
morbidity and mortality as these conditions are major risk factors for cardiovascular events. In fact,
cardiovascular diseases are the leading cause of death globally, accounting for about 17.9 million deaths
every year [8,9]. A range of factors including diabetes, lack of physical activities, poor dietary habits,
and lifestyle choices have been implicated in the development of this condition [8,10]. There is also an
increased risk of metabolic syndrome and diabetes in people who abuse substances due to nutritional
deficiencies and increased cell damage [11]. According to Najafipour and Beik [12], while opium
may temporarily increase blood lipids, its long term use may aggravate diabetes and dyslipidemia.
In contrast, limiting substance use in patients with type 2 diabetes can improve clinical outcomes [13].
Despite these findings, it would appear that there is limited research on the impact of substance
abuse including opium in people with diabetes and its role in lipid metabolism due in part to the
nature of illicit drug use and the difficulty in conducting accurate assessment [13–15]. Patients with
diabetes using opioids have been found to be less likely to receive recommended glycated hemoglobin
and blood lipids testing and are more likely to experience diabetes-related hospitalizations than those
not using opioids [13]. In addition, the effect of opium abuse on lipid profile in patients with diabetes
remains inconsistent [12]. In our previous review [16], we found that substance abuse significantly
lowered fasting blood glucose in patients with diabetes compared with control although differences
were not significant with respect to postprandial blood glucose and glycated hemoglobin. Therefore,
this review is a follow-up to our earlier review.
1.2. Aim
This was a systematic review and meta-analysis which evaluated the impact of opium abuse on
lipid profile in patients with diabetes.
2. Method
This systematic review and meta-analysis was conducted in line with the preferred reporting
items for systematic reviews and meta-analyses (PRISMA) guidelines [17].
2.1. Types of Studies
The studies included in this review were cross-sectional and case-control studies.
2.2. Types of Participants
All the participants included in this study were patients with diabetes (type 1 and type 2 diabetes).
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2.3. Types of Interventions
People with diabetes who abused opium were compared with people with diabetes who did not
abuse opium (control).
2.4. Outcome Measures
The following were the primary outcomes of interest: (1) Total cholesterol (TC) (mmol/L),
(2) High-density lipoprotein (HDL) cholesterol (mmol/L), (3) Low-density lipoprotein (LDL) cholesterol
(mmol/L), (4) Triglyceride (TG) (mmol/L). A secondary outcome of interest was body mass index
(BMI) kg/m2.
2.5. Data Sources and Search Strategy
Three databases (Embase, PubMed, and PsycINFO) plus Google scholar were searched
independently by two researchers (O.O., O.O.O.) for relevant articles from database inception to
18 July 2019. The search terms included synonyms and medical subject headings (MeSH) and these
were combined using Boolean operators (AND/OR) in accordance with the Population, Intervention,
Comparator, and Outcomes (PICO) framework (Table 1) [18]. The articles obtained from the different
databases were exported to EndNote (Analytics, Philadelphia, PA, USA) for de-duplication.
Table 1. Search Terms and Search Strategy.
Patient/Population Intervention Comparator Outcomes of Interest Combining Search Terms
Patients with diabetes Substance Abuse Lipid Profile and BodyMass Index
Type 2 diabetes OR
type 1 diabetes OR
diabetes complications
OR diabetes mellitus,
type 2 OR diabetes
mellitus, type 1 OR
diabetes mellitus
Substance-related disorders
OR substance* OR marijuana
abuse OR
amphetamine-related
disorders OR cocaine-related
disorders OR opioid-related
disorders OR opiate* OR
opioid* OR heroin dependence
Body mass index OR BMI
OR Total cholesterol OR
High-density lipoprotein
cholesterol OR HDL OR
Low-density lipoprotein
cholesterol OR LDL OR
Triglycerides
Column 1 AND Column 2
AND Column 3
*(Truncation symbol).
2.6. Study Selection
Articles were identified and screened using the abstracts and titles independently by two
researchers (O.O., O.O.O.) and checked by two other researchers (X.-H.W., J.I.) (Figure 1). Based on
the agreed inclusion and exclusion criteria by the four researchers, eligible articles were selected for
inclusion in the systematic review and meta-analysis using the full text of the articles.
2.7. Inclusion and Exclusion Criteria
The following were the criteria for inclusion: Studies with (1) patients with type 1 and type 2
diabetes who were substance abusers, (2) case-control study, cross-sectional study, and retrospective
cohort study, (3) outcomes of interest (lipid profile and body mass index).
Exclusion criteria were studies with: (1) Subjects with gestational diabetes, (2) outcomes without
lipid profile, (3) participants abusing an unknown substance.
2.8. Rationale for the Studies Selected
The selection of studies was based on set criteria outlined above and only the studies that met
these criteria were included in this review. Therefore, on this occasion, the studies that met the inclusion
criteria were only those conducted in Iran. Other studies that were carried out in other countries
around the world were also screened for eligibility and possible inclusion, but, were excluded due
to not meeting the inclusion criteria. For example, Saunders et al. [19] study, which was conducted
in the UK, was excluded from this review because the type of substance abused was not stated in
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the study. In addition, many other studies including Modzelewski et al. [20] study, conducted in
USA, Lee et al. [21] study conducted in Australia, Saif-Ali et al. [22] study, carried out in Yemen,
Isidro and Jorge [23] study, carried out in Spain, and Warner et al. [24] study, conducted in USA
examined the effect of abuse of different substances in patients with diabetes. However, the outcome
measures of cardio-metabolic significance in these studies were blood glucose parameters which are
not the focus of the current review. None of these studies included lipid profile as measures of interest,
hence, they were excluded from this review.
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Figure 1. PRISMA FLOW CHART.
2.9. Data Extraction
Two researchers (O.O. and O.O.O.) extracted the data from the articles and these were cross-checked
by two other researchers (X.-H.W. and J.I.).
2.10. Quality Evaluation
The Risk of Bias In Non-Randomised Studies of Interventions (ROBINS-I) assessment tool [25]
was used to evaluate the quality of the studies included. These were in relation to the bias due to
confounding, selection of participants into the study, classification of interventions, deviations from
intended interventions, missing data, measurement of outcomes, selection of the reported result [25].
The risk of bias could be classified as low, moderate, serious or critical [25]. The process of the
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evaluation of the risk of bias was conducted by two researchers (O.O., O.O.O.) and cross-checked by
the two other researchers (X.-H.W., J.I.). Only the data/information available in the studies selected
were used to evaluate the different studies.
2.11. Statistical Analysis
The meta-analysis and sensitivity analysis were conducted using the Review Manager (RevMan
5.3 The Cochrane Collaboration, Copenhagen, Denmark) [26,27] and the random-effects models were
used for the analysis due to the differences in the design of the studies included. Forest plots were
used to illustrate the outcomes of the meta-analysis. A p value of <0.05 was considered as a measure of
statistical significance for the overall effect of the intervention, whereas, the statistic I2 on a scale of
0–100% was used as the measure of heterogeneity across the studies. In addition, a p value of 0.1 was
used to determine statistical significance of heterogeneity.
2.12. Data Inclusion Decisions
Data that were presented in mg/dL were converted to mmol/L when conducting the meta-analysis.
The results for the Mohammadali et al. [28] and Rahimi et al. [29] studies which did not state whether
values were a standard deviation or standard error of mean were recalculated using the means, sample
sizes and the measures of dispersion [26] and the findings were comparable to standard deviation.
3. Results
Six studies published between 2004 and 2014 were selected for this systematic review and
meta-analysis (Tables 2 and 3). All the studies were conducted in Iran. Participants in five of the
studies had type 2 diabetes while 91% in one study had people with type 2 diabetes. The type of
substance abused was opium in all the studies. While four of the studies were cross-sectional studies,
two were case-control studies.
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Table 2. Characteristics of the articles included in this review (N = 6)
Study Reference Country Length of Study Study Type/Design Sample Size/Description Age Gender Diabetes Type/Duration ofDiabetes (YRS- Mean ± SD)
Type of
Substance Abused
Azod et al. [30] Iran Not stated Cross-sectional study
23 opium
46 non-opium
The two groups were matched in age, BMI,
duration of diabetes, cigarette smoking,
medication, and education
Mean 60.52 ± 12.25
55.24 ± 10.92 years All males
Type 2 DM
Duration of diabetes recorded
during the study, but not reported
by authors.
Opium
Hosseini et al. [31] Iran 2008–2010 Cross-sectional study
228 opium
228 non-opium
The two groups were matched in age, BMI,
sex and smoking status
Mean 58.9 (SD = 9.2 years 92% male
91% were type 2 DM
Opium: 7.6 ± 7.1
non Opium: 8.2 ± 8.4
Opium
Karam et al. [32] Iran Not stated Case-control study
23 male and 26 female opium
23 male and 26 female non-opium
The two groups were matched in age, BMI,
cigarette smoking and medication
35–65 years 53% female
Type 2 DM
Duration of diabetes was not
reported
Opium
Mohammadali et al. [28] Iran 2006–2007 Cross-sectional study
48 opium users
49 non-opium users
The two groups were matched in age, BMI,
duration of diabetes and medication history
Mean 64 years >60% female
Type 2 DM
Opium: 11.31 ± 6.33
non Opium: 10.39 ± 7.91
Opium
Rahimi et al. [29] Iran Not stated Cross-sectional study
179 opium users
195 non-opium users
The two groups were not matched in age, BMI
and cigarette smoking
Mean 53.5–58.2 years
Combined
males and
females
Type 2 DM
Duration of diabetes was not
reported
Opium
Rezvanfar et al. [33] Iran 2009–2010 Case-control study
88 opium users
144 non-opium users
The two groups were matched in age, BMI,
duration of diabetes
Mean 55–57 years All males
Type 2 DM
Opium: 9.8 ± 6.4
non Opium: 7.8 ± 5.4
Opium
Abbreviation: BMI (Body Mass Index).
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Table 3. Blood lipid Indicators of patients with diabetes based on their substance use status.
Study reference Participants Studied Body Mass Index(BMI) (kg/m2) Total Cholesterol
High Density
Lipoprotein (HDL)
Low Density
Lipoprotein (LDL) Triglycerides
Azod et al. [30]
Substance abusers
Mean ± SD 26.64 ± 4.27 No data 34.98 mg/dL 123.96 ± 34.96 mg/dL 31.50 mg/dL
Non-substance abusers 26.25 ± 3.47P = 0.68 No data
35.01 mg/dL
P = 0.99
111.24 ± 29.57 mg/dL
P = 0.11
36.75 mg/dL
P = 0.30
Hosseini et al. [31]
Substance abusers
Mean ± SD 27.2 ± 4.1 180.96 ± 46.85 mg/dL 39.67 ± 8.80 mg/dL 105.82 ± 39.76 mg/dL 179.68 ± 103.15 mg/dL
Non-substance abusers 27.5 ± 4.1P = 0.391
189.85 ± 52.14 mg/dL
P = 0.061
40.08 ± 9.70 mg/dL
P = 0.640
109.63 ± 41.76 mg/dL
P = 0.343
209.59 ± 142.12 mg/dL
P = 0.012
Karam et al. [32] (for men)
Substance abusers
Mean ± SEM 23.92 ± 0.68 5.53 ± 0.2 mmol/L 1.035 ± 0.066 mmol/L No data 2.34 ± 0.2 mmol/L
Non-substance abusers 22.88 ± 0.60P = 0.2598
6.1 ± 0.28 mmol/L
P = 0.098
1.32 ± 0.094 mmol/L
P = 0.0376 No data
2.09 ± 0.18 mmol/L
P = 0.3481
Karam et al. [32] (for women)
Substance abusers
Mean ± SEM 23.73 ± 0.80 6.21 ± 0.28 mmol/L 1.36 ± 0.08 mmol/L No data 3.02 ± 0.25 mmol/L
Non-substance abusers 24.31 ± 0.72P = 0.2200
6.97 ± 0.29 mmol/L
P = 0.0711
1.27 ± 0.08 mmol/L
P = 0.3483 No data
2.79 ± 0.19 mmol/L
P = 0.5349
Mohammadali et al. [28]
Substance abusers
Mean ± SD 24.65 ± 5.22 182.27 ± 53.23 mg/dL 39 ± 10.4 mg/dL 113.6 ± 39.25 mg/dL 164.46 ± 84.65 mg/dL
Non-substance abusers 25.79 ± 3.5P = 0.153
174.88 ± 47.89 mg/dL
P = 0.307
37.47 ± 9.24 mg/dL
P = 0.477
104.86 ± 42.1 mg/dL
P = 0.171
173.49 ± 127.61 mg/dL
P = 0.751
Rahimi et al. [29]
Substance abusers
Mean ± SD 26.3 ± 5.6 194.1 ± 49.6 mg/dL 38.6 ± 10.9 mg/dL 117.6 ± 40.7 mg/dL 201.5 ± 157.3 mg/dL
Non-substance abusers 27.7 ± 4.4P = 0.009
196.9 ± 40.6 mg/dL
P = 0.550
49.8 ± 12.2 mg/dL
P < 0.001
109.4 ± 34.2 mg/dL
P = 0.052
200.1 ± 99.8 mg/dL
P = 0.910
Rezvanfar et al. [33]
Substance abusers
Mean ± SD No data 174 ± 34 mg/dL 38 ± 7 mg/dL 107 ± 28 mg/dL 164 ± 88 mg/dL
Non-substance abusers No data 182 ± 27 mg/dLP = 0.18
38 ± 12 mg/dL
P = 0.90
108 ± 24 mg/dL
P = 0.92
220 ± 86 mg/dL
P = 0.005
Abbreviations: SD (Standard deviation), SEM (Standard Error of Mean).
Int. J. Environ. Res. Public Health 2019, 16, 4795 8 of 13
3.1. Assessment of Risk of Bias of Included Studies
All the studies included in this review demonstrated a low risk of bias in all the domains assessed
and had a low overall risk of bias (Figure 2).
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In relation to LDL cholesterol, the difference was also not statistically significant (P > 0.05) between
the opium abuse and the control groups with a mean difference of 0.8 (95% CI, −0.08, 0.23) (Figure 7).
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4. Discussion
The results of the systematic review and meta-analysis have shown that opium abuse has a
significant effect (P < 0.05) on total cholesterol although the results of the sensitivity analysis did not
demonstrate consistency in two of the studies [31,33] (Figure 3b). In addition, the effect of opium abuse
on HDL cholesterol, triglycerides, LDL cholesterol, and body mass index was not significantly different
(P > 0.05) compared with the control.
The findings of this review appear similar to the outc me f an earlier review [12] hich evaluated
the impact of opium on blood glucose and serum lipids in humans and imals. Although the study
by Najafipour and Beik [12] was not a systematic revi w, it demonstrated that there were diff renc s in
the outcomes of the various studies on the impact of opium on lipid indices n humans. While some
studies on h al hy and patien s with diabetes have shown no significant ass ciation between substance
a use and triglycerides, total cholesterol, LDL cholesterol, and HDL cholesterol, other studies have
revealed that substance abuse has a harmful effect on one or ore of lipid parameters [12].
In the current review, Karam et al. [32] found that opium abuse decreased HDL cholesterol and
that total cholesterol tended to be lower in males who abused opium. On the other hand, Azod et al. [30]
found no significant differences (P > 0.05) between the opium abuse group and the control group with
respect to triglyceride, total cholesterol, LDL and HDL cholesterol. Rezvanfar et al. [33] noted that
serum triglyceride in patients with diabetes who abused opium was significantly lower (P = 0.005)
compared with control, while Mohammadali et al. [28] did not find significant difference (P > 0.05)
between the opium abuse and control groups with respect to serum lipids.
The differences observed in the findings of some of the studies with respect to triglyceride,
HDL and LDL cholesterol in this review could be due to differences in the sample size of the studies
and the route of administration of the substances [34]. In addition, it could be due to the frequency
of substance abused, the duration of drug dependency, socio-demographic characteristics and other
comorbidities [11,12,16,18]. o ever, the significant decrease in total cholesterol in the participants
who abused opium ay t tritional deficiencies. For example, Kouros et al. [35] concluded
that low levels of lipids i lesterol and triglycerides that are found in people who abuse
substances are mainly due to drug-abuse associated malnutrition. There is evidence that substance
abuse leads to loss of appetite in individuals who abuse drugs [34].
Asgary et al. [34] noted that nutritional habits, social status, and poor lifestyle may influence
lipid profiles in individuals. The authors further reported that malnutrition in people who abuse
substances could be a result of economic problems and/or individual choices. Furthermore, because
opioids are metabolized mainly in the liver, chronic opium consumption may cause liver damage [12].
The liver plays a significant role in the metabolism of lipids, thus, chronic liver diseases may cause
dysregulation of serum lipids [12]. In addition, opium suppresses appetite and reduces weight,
therefore, the reduction in lipids may not be due to the direct effect of opium, instead it could be the
result of weight loss or nutritional deficiency [12]. This position reaffirms the views expressed by
Rahimi et al. [29] who observed that food regimen, malnutrition and physical activity which could be
different in patients with diabetes who abuse opium compared with control are possible factors that
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could influence the level of cholesterol. Another possible factor that may affect the level of cholesterol
in these subjects could be the impact of medications being administered to them [29]. However, in the
current review, three studies [28,30,32] matched the patients with diabetes who abused opium with
control in their medications. For example, Mohammadali et al. [28] noted that the participants in their
study were on a range of medications including sulfonylurea agents, biguanides, insulin and statins
and the two groups were matched in medications. Although the three other studies [29,31,33] did not
discuss the medication history of the participants, the matching of the two groups in medications in
the three other studies [28,30,32] would suggest a lesser role for medications in the current review with
respect to the impact of opium abuse on cholesterol.
In relation to the BMI, the results which showed no significant difference (P > 0.05) between the
group that abused opium and the control could be due to the fact that the two groups were matched
for BMI in all the studies except in the Rahimi et al. [29] study where the mean BMI was significantly
lower in the opium abuse group compared with the non-opium abuse group.
In terms of its public health significance, the findings of this review may be of relevance in the
area of promoting adequate nutritional intake in patients with diabetes who abuse opium. In addition,
the decrease in total cholesterol [36], underscores the potential impact of opium abuse on lipid
metabolism in patients with diabetes.
Limitations
All the studies included in this review were conducted in Iran, and this may affect its wider
application. The Mohammadali et al. [28] and Rahimi et al. [29] studies did not state whether the data
presented were expressed as means ± SD or means ± SEM. Although the SD was calculated based on
the means, sample sizes and measures of dispersion and these were found comparable to the results
presented, the non-inclusion of these information are limitations of those studies.
5. Conclusions
The findings of this systematic review and meta-analysis have shown that opium abuse significantly
decreased (P< 0.05) total cholesterol in patients with diabetes. However, with respect to HDL cholesterol,
triglycerides, BMI and LDL cholesterol, the differences were not statistically significant (P > 0.05)
compared with control. This result may have public health significance in terms of ensuring the
promotion of adequate nutritional intake in patients with diabetes who abuse opium. More studies are
needed in order to fully understand the effect of opium abuse on lipid profile in patients with diabetes.
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